Suppr超能文献

[过氧化物酶体神经疾病与雷夫叙姆病:极长链脂肪酸和植烷酸作为诊断标志物]

[Peroxisomal neurologic diseases and Refsum disease: very long chain fatty acids and phytanic acid as diagnostic markers].

作者信息

Molzer B, Stöckler S, Bernheimer H

机构信息

Neurologisches Institut der Universität Wien.

出版信息

Wien Klin Wochenschr. 1992;104(21):665-70.

PMID:1282286
Abstract

Peroxisomal disorders are genetic metabolic diseases with generalized, multiple, or single functional disturbances of the peroxisome. According to the extent of the functional disturbances 3 groups of diseases can be differentiated: disorders with generalized loss of peroxisomal functions (Zellweger syndrome, ZS; neonatal adrenoleukodystrophy, NALD; infantile Refsum's disease), disorders with multiple enzymatic defects (e.g. rhizomelic chondrodysplasia punctata), and disorders with a single enzymatic defect in the peroxisome, the most important being adrenoleukodystrophy/adrenomyeloneuropathy (ALD/AMN). Adult Refsum's disease, a genetic neurological disorder with phytanic acid accumulation, is due to a mitochondrial enzyme deficiency, but is often considered together with peroxisomal diseases because of phytanic acid (PHYT) accumulation in most peroxisomal diseases. The main clinical and pathological criteria of the major disorders and the biochemical parameters of their differentiation are presented. Elevated levels of very long chain fatty acids (VLCFA) and/or PHYT are the primary diagnostic markers for all peroxisomal disorders and adult Refsum's disease, respectively. Our investigations disclosed 30 ALD/AMN hemizygotes, 16 ALD/AMN heterozygotes, 8 cases of ZS/NALD and 7 patients with adult Refsum's disease. In addition, 15 cases of peroxisomal disorders were confirmed by biochemical investigations in autopsy material. With regard to peroxisomal disorders, therapeutic concepts exist only for ALD/AMN: corticosteroid substitution for adrenal insufficiency, dietary treatment, and bone marrow transplantation (BMT). Adult Refsum's disease can be treated successfully by dietary therapy. In case of dietary treatment and BMT, assay of VLCFA and/or PHYT is important for the biochemical evaluation of these therapies.

摘要

过氧化物酶体病是一类遗传性代谢疾病,其过氧化物酶体存在广泛、多样或单一的功能障碍。根据功能障碍的程度,可将疾病分为3组:过氧化物酶体功能全面丧失的疾病(泽尔韦格综合征,ZS;新生儿肾上腺脑白质营养不良,NALD;婴儿型雷夫叙姆病)、存在多种酶缺陷的疾病(如肢根型点状软骨发育不良)以及过氧化物酶体存在单一酶缺陷的疾病,其中最重要的是肾上腺脑白质营养不良/肾上腺脊髓神经病(ALD/AMN)。成人雷夫叙姆病是一种伴有植烷酸蓄积的遗传性神经疾病,由线粒体酶缺乏所致,但由于在大多数过氧化物酶体病中也有植烷酸(PHYT)蓄积,故常与过氧化物酶体病一并考虑。文中介绍了主要疾病的主要临床和病理标准及其鉴别的生化参数。极长链脂肪酸(VLCFA)水平升高和/或PHYT分别是所有过氧化物酶体病和成人雷夫叙姆病的主要诊断标志物。我们的研究发现了30例ALD/AMN半合子、16例ALD/AMN杂合子、8例ZS/NALD病例以及7例成人雷夫叙姆病患者。此外,尸检材料的生化检查确诊了15例过氧化物酶体病。关于过氧化物酶体病,目前仅针对ALD/AMN有治疗方案:针对肾上腺功能不全进行皮质类固醇替代治疗、饮食治疗以及骨髓移植(BMT)。成人雷夫叙姆病可通过饮食疗法成功治疗。在进行饮食治疗和BMT时,检测VLCFA和/或PHYT对于这些疗法的生化评估很重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验